On March 4, 2021, Patrick Balthrop, a director of Personalis, Inc. resigned as a member of the Company's Board of Directors (the Board"), which resignation became effective on March 5, 2020. Mr. Balthrop's resignation was not the result of any disagreement or dispute with the Company. On March 5, 2021, upon recommendation of the Nominating and Corporate Governance Committee of the board appointed Woodrow (Woody) A. Myers, Jr., M.D., to the Board as a Class I director, which appointment became effective on March 6, 2021. Dr. Myers' term will expire, along with the terms of the other Class I directors, at the Company's annual meeting of stockholders in 2023. The Board also appointed Dr. Myers to serve as a member of the Nominating Committee.
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
PERSONALIS, INC. 
